StockData
AnaptysBio, Inc logo

AnaptysBio, Inc (ANAB) stock

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30
$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $2.28BP/E –Yield –

Earnings

AnaptysBio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 2, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$30.30M
-60.3% on a year earlier
EPS, Q3 FY2026
$0.11
$0.52 a year earlier
Latest guidance
Raised
Nov 2, 2023 · 1 item

Quarterly results

Revenue and earnings per share from each of AnaptysBio's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 2, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026after the close$30.30M-60.3%$0.11Release
Q1 FY2026ended Mar 31, 2026May 12, 2026after the close$25.60M-7.9%-$1.84Release
Q4 FY2025ended Dec 31, 2025Mar 3, 2026after the close$108.20M+151.0%$1.58Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025after the close$76.30M+154.3%$0.52Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close$22.30M+102.7%-$1.34Release
Q1 FY2025ended Mar 31, 2025May 5, 2025after the close$27.80M+286.1%-$1.28Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$43.10M+378.9%-$0.72Release
Q3 FY2024ended Sep 30, 2024Nov 5, 2024after the close$30.00M+809.1%-$1.14Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024after the close$11.00M+214.3%-$1.71Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$7.20M+414.3%-$1.64Release
Q4 FY2023ended Dec 31, 2023Mar 11, 2024after the close$9.00M+32.4%-$1.59Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period AnaptysBio guided for has been reported

Guidance history

Every forecast AnaptysBio put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 2, 2023cash and investmentsFY2023$400.00M – $410.00MRaised
Aug 7, 2023cash and investmentsFY2023$380.00M – $395.00MRaised
May 11, 2023cash and investmentsFY2023$370.00M – $385.00MNew
Aug 8, 2022net cash burnFY2022$90.00M – $100.00MReaffirmed
May 4, 2022net cash burnFY2022$90.00M – $100.00MNew
Nov 4, 2021cashFY2021$600.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases AnaptysBio filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. Update
  5. Update
  6. Update
  7. Results
  8. Results
  9. Results
  10. Update
  11. News
  12. Update
  13. Update
  14. Results
  15. Update

See a number that looks wrong?